Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Thursday 8 March 2018, 10:00-15:10

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh, Chair Present for all notes
2. Dr Lindsay Smith, Vice Chair Present for all notes
3. Dr Nabeel Alsindi Present for all notes
4. Dr Aomesh Bhatt Present for all notes
5. Professor David Bowen Present for all notes
6. Dr Matthew Bradley Present for all notes
7. Mrs Susan Dutton Present for all notes
8. Professor Rachel Elliott Present for all notes
9. Mrs Gillian Ells Present for all notes
10. Professor Paula Ghaneh Present for notes 10 to 29
11. Dr Peter Hall Present for all notes
12. Rebecca Harmston Present for all notes
13. Dr Robert Hodgson Present for all notes
14. Libby Mills Present for all notes
15. Mr Malcolm Oswald Present for all notes
16. Dr Paula Parvulescu Present for all notes

In attendance:
Lucy Beggs Technical Analyst, National Institute for Health and Care Excellence Present for notes 17 to 28
Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes
Professor Peter Clark CDF Clinical Lead, NHS Expert Present for all notes
Melanie Costin Support Services Manager, Patient Expert, nominated by Fight Bladder Cancer Present for notes 5 to 13
Ross Dent Technical Analyst, National Institute for Health and Care Present for notes 1 to 16
<table>
<thead>
<tr>
<th>Name</th>
<th>Role and Nominated By</th>
<th>Present Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Edwards</td>
<td>ERG representative, BMJ Group</td>
<td>17 to 25</td>
</tr>
<tr>
<td>Dr Alastair Greystoke</td>
<td>Senior Lecturer and Honorary Consultant, Clinical Expert, nominated by Pfizer</td>
<td>17 to 25</td>
</tr>
<tr>
<td>Christian Griffiths</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>17 to 28</td>
</tr>
<tr>
<td>Kayleigh Kew</td>
<td>ERG representative, BMJ Group</td>
<td>17 to 25</td>
</tr>
<tr>
<td>Allen Knight</td>
<td>Chair – Action Bladder Cancer UK, Patient Expert, nominated by Action Bladder Cancer UK</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>All notes</td>
</tr>
<tr>
<td>Gemma Marceniuk</td>
<td>ERG representative, BMJ Group</td>
<td>17 to 25</td>
</tr>
<tr>
<td>Kate Moore</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>All notes</td>
</tr>
<tr>
<td>Kate Ren</td>
<td>ERG representative, School of Health and Related Research (ScHARR)</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Dr Riyaz Shah</td>
<td>Consultant Medical Oncologist, Clinical Expert, nominated by Roche</td>
<td>17 to 25</td>
</tr>
<tr>
<td>Hazel Squires</td>
<td>ERG representative, School of Health and Related Research (ScHARR)</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Dr Santhanam Sundar</td>
<td>Consultant Oncologist, Clinical Expert, nominated by BUG-</td>
<td>5 to 13</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable and alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

2. The Chair welcomed Libby Mills to her first meeting as a member of the Appraisal Committee.

3. Apologies were received from Dr Bernard Khoo, Sumithra Maheswaran, Dr David Meads and Professor Oluwafemi Oyebode.
Any other Business

4. There was no AOB.

Appraisal of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Peter Clark, Melanie Costin, Allen Knight, Kate Ren Hazel Squires and Dr Santhanam Sundar to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Merck Sharp and Dohme to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghanem, Rebecca Harmanston, Dr Robert Hodgson, Libby Mills, Mr Malcolm Oswald and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.

7.2. Dr Peter Hall declared a non-personal, non-specific financial interest as his department within NHS Lothian had received research funding from Roche and Eli Lilly (comparators).

9.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab
for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.

10. The Chair introduced the lead team, Professor Paula Ghaneh, Dr Peter Hall and Dr Rebecca Harmston, who gave presentations on the clinical effectiveness and cost effectiveness of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209].

15.1. The committee decision was based on consensus

16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer [ID925]

Part 1 – Open session

17. The Chair welcomed the invited experts: Dr Peter Clark, Steve Edwards, Dr Alastair Greystoke, Kayleigh Kew, Gemma Marceniuk and Dr Riyaz Shah to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Roche to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Rebecca Harmston, Dr Robert Hodgson, Libby Mills, Mr Malcolm Oswald and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal
non-specific family interest for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

19.2. Dr Peter Hall declared a non-personal, non-specific financial interest as his department within NHS Lothian had received research funding from Roche, Pfizer and Eli Lilly (comparators).

9.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

20. The Chair asked all NICE Staff to declare any relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer [ID925].

21. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

21.1. Dr Peter Clark, Steve Edwards, Dr Alastair Greystoke, Kayleigh Kew and Gemma Marceniuk declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

21.2. Dr Riyaz Shah declared a personal non-specific financial interest as he acts as an advisor to several companies involved in making ALK inhibitors. This involves remunerated roles as an adviser as well as delivering lectures/training. Dr Shah also declared that he is involved with clinical trials of some ALKi agents and has such relationships with Roche, Pfizer, Novartis and Takeda.

21.2.1. It was agreed that this declaration would not prevent Dr Riyaz Shah from participating in this section of the meeting.

22. The Chair introduced the lead team, Dr Nabeel Alsindi, Rebecca Harmston and Mr Malcolm Oswald, who gave presentations on the clinical effectiveness and cost effectiveness of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.

27. The Committee continued to discuss the clinical and cost effectiveness of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
   27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

29. Wednesday 11 April 2018, 10:00, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.